60 Degrees Pharmaceuticals, Inc.
SXTPHealthcare|Biotechnology|US
$0.59
-0.32 (-35.08%)
Tangible Book / Share
$0.84
Cash / Share
$0.39
Financials
Financial Snapshot
Market Cap
$2.1M
Enterprise Value
$1.2M
Revenue (TTM)
$1.1M
Net Income (TTM)
-$8.1M
Cash & Investments
$1.0M
Net Cash
$871.4K
Free Cash Flow (TTM)
-$9.0M
Operating CF (TTM)
-$8.8M
Debt/Equity
0.06
Cash Runway & Burn Rate
Cash on Hand
$1.0M
Quarterly Burn
$2.2M
Monthly Burn
$731.2K
Est. Runway
~0.5 quarters
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $191.7K | $115.4K | $264.9K | $2.1M | $3.4M | $2.8M | $1.0M | |
| Operating Cash Flow | -$167.3K | -$649.1K | -$1.0M | -$4.5M | -$5.6M | -$6.8M | -$8.8M | |
| Free Cash Flow | -$238.3K | -$684.5K | -$1.1M | -$4.7M | -$5.8M | -$7.1M | -$9.0M | |
| Capital Expenditure | -$71.0K | -$35.4K | -$60.1K | -$115.9K | -$181.1K | -$218.1K | -$175.4K | |
| Financing Cash Flow | $277.4K | $611.2K | $1.2M | $6.5M | $7.1M | $6.4M | $8.1M |
R&D Spending
R&D (TTM)
$2.3M
R&D Intensity
209.6%
R&D Growth vs Prior
+10.6%
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $1.2M | $223.2K | $253.6K | $607.6K | $1.0M | $1.1M | |
| R&D Expense | $806.7K | $5.5M | $525.6K | $691.8K | $5.0M | $2.1M | $2.3M | |
| R&D % of Revenue | 37.0% | 474.9% | 235.5% | 272.8% | 820.7% | 209.5% | 209.6% | |
| SG&A | $1.5M | $1.1M | $1.3M | $4.2M | $5.0M | $6.3M | $6.6M |
Income Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $1.2M | $223.2K | $253.6K | $607.6K | $1.0M | $1.1M | |
| Cost of Revenue | $703.0K | $850.7K | $432.4K | $474.6K | $384.8K | $781.7K | $895.2K | |
| Gross Profit | $1.5M | $309.6K | -$209.2K | -$221.0K | $222.8K | $223.8K | $215.8K | |
| R&D | $806.7K | $5.5M | $525.6K | $691.8K | $5.0M | $2.1M | $2.3M | |
| SG&A | $1.5M | $1.1M | $1.3M | $4.2M | $5.0M | $6.3M | $6.6M | |
| Operating Income | -$418.1K | -$1.1M | -$1.8M | -$5.2M | -$9.7M | -$7.8M | -$8.6M | |
| Interest Expense | $2.7M | $3.2M | $4.0M | $2.3M | $7.9K | $7.8K | $7.6K | |
| Pretax Income | -$3.0M | -$4.3M | -$6.2M | -$3.8M | -$8.0M | -$7.4M | -$8.1M | |
| Net Income | -$3.0M | -$4.3M | -$6.2M | -$3.8M | -$7.9M | -$7.4M | -$8.1M | |
| EPS (Diluted) | -2.08 | -2.96 | -4.28 | -3.80 | -74.20 | -11.73 | -6.05 | |
| EBITDA | -$341.2K | -$1.0M | -$2.1M | -$1.4M | -$7.9M | -$7.3M | -$8.0M | |
| Shares Out. (M) | 0.02 | 0.02 | 0.02 | 0.02 | 0.11 | 0.67 | 2.65 |
Balance Sheet
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $191.7K | $115.4K | $264.9K | $2.1M | $1.7M | $1.5M | $1.0M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $1.7M | $1.2M | $0.00 | |
| Total Current Assets | $2.4M | $1.2M | $1.1M | $7.2M | $5.4M | $4.9M | $3.7M | |
| Total Assets | $2.6M | $1.4M | $1.3M | $7.8M | $5.8M | $5.4M | $4.3M | |
| Total Current Liabilities | $1.4M | $635.5K | $23.9M | $2.8M | $1.7M | $1.8M | $1.6M | |
| Long-Term Debt | $15.9M | $18.7M | $1.3M | $150.3K | $147.1K | $144.0K | $149.2K | |
| Total Liabilities | $20.7M | $19.5M | $25.4M | $3.0M | $1.8M | $2.0M | $1.8M | |
| Stockholders' Equity | -$17.5M | -$17.6M | -$23.6M | $4.9M | $4.0M | $3.5M | $2.6M | |
| Retained Earnings | -$18.4M | -$22.6M | -$28.8M | -$32.6M | -$40.5M | -$47.9M | -$52.2M |
Cash Flow Statement
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$167.3K | -$649.1K | -$1.0M | -$4.5M | -$5.6M | -$6.8M | -$8.8M | |
| Capital Expenditure | -$71.0K | -$35.4K | -$60.1K | -$115.9K | -$181.1K | -$218.1K | -$175.4K | |
| Free Cash Flow | -$238.3K | -$684.5K | -$1.1M | -$4.7M | -$5.8M | -$7.1M | -$9.0M | |
| Investing Cash Flow | -$71.0K | -$35.4K | -$60.1K | -$115.9K | -$1.9M | $254.9K | -$288.3K | |
| Financing Cash Flow | $277.4K | $611.2K | $1.2M | $6.5M | $7.1M | $6.4M | $8.1M | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $6.5M | $7.0M | $6.5M | $8.1M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $277.4K | $611.2K | $1.1M | -$961.1K | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $3.6M | $456.3K | $112.0K | |
| Net Change in Cash | -$95.2K | -$76.3K | $149.5K | $1.9M | -$483.1K | -$149.3K | -$944.3K |
Dilution Tracker
Shares outstanding grew 2668.6% over 5 years — significant dilution
Shares Outstanding
4M
5-Year Share Growth
+2668.6%
Stock Issuance (TTM)
$8.1M
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.02 | 0.02 | 0.02 | 0.02 | 0.11 | 0.67 | 2.65 | |
| Change vs Prior % | — | 0.0% | 0.0% | 0.0% | 369.5% | 489.6% | 296.0% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $6.5M | $7.0M | $6.5M | $8.1M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $3.6M | $456.3K | $112.0K |
Margins & Profitability
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 67.8% | 26.7% | -93.7% | -87.1% | 36.7% | 22.3% | 19.4% | |
| Operating Margin % | -19.2% | -96.9% | -784.2% | -2032.8% | -1599.0% | -771.6% | -774.9% | |
| Net Margin % | -139.1% | -366.4% | -2769.5% | -1485.1% | -1308.0% | -732.8% | -730.2% | |
| EBITDA Margin % | -15.6% | -87.5% | -944.9% | -562.6% | -1297.6% | -723.8% | -720.9% | |
| FCF Margin % | -10.9% | -59.0% | -479.4% | -1837.3% | -959.4% | -702.9% | -805.6% | |
| ROE % | 17.3% | 24.2% | 26.2% | -77.3% | -196.9% | -212.8% | -211.6% | |
| ROA % | -116.4% | -305.1% | -476.5% | -48.4% | -138.0% | -137.3% | -189.4% | |
| ROIC % | -35.7% | -125.1% | 118.6% | -103.7% | -236.3% | -219.7% | -321.2% | |
| R&D / Revenue % | 37.0% | 474.9% | 235.5% | 272.8% | 820.7% | 209.5% | 209.6% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | -46.8% | -80.8% | 13.6% | 139.6% | 65.5% | |
| Gross Profit | 0.0% | -79.1% | -167.6% | -5.6% | 200.8% | 0.4% | |
| Operating Income | 0.0% | -168.8% | -55.7% | -194.5% | -88.5% | 20.1% | |
| Net Income | 0.0% | -40.1% | -45.4% | 39.1% | -111.0% | 7.3% | |
| EPS (Diluted) | 0.0% | -42.3% | -44.6% | 11.2% | -1852.6% | 84.2% | |
| Operating Cash Flow | 0.0% | -288.0% | -55.6% | -349.8% | -24.3% | -21.3% | |
| Free Cash Flow | 0.0% | -187.3% | -56.3% | -335.4% | -25.1% | -21.2% | |
| R&D Expense | 0.0% | 583.2% | -90.5% | 31.6% | 620.8% | -57.8% | |
| SG&A Expense | 0.0% | -23.5% | 16.9% | 225.4% | 18.5% | 25.0% | |
| Total Assets | 0.0% | -46.5% | -6.9% | 500.0% | -26.0% | -6.8% | |
| Book Value / Share | 0.0% | -0.5% | -33.0% | 119.9% | -82.4% | -85.5% | |
| Debt | 0.0% | 18.1% | 19.2% | -99.2% | -9.7% | -2.0% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 0.0% | 369.5% | 489.6% |
Valuation
P/E (TTM)At Loss
P/S1.88
10Y Low / Med / High1.35 / 23.37 / 121.82
P/B0.60
10Y Low / Med / High0.39 / 0.73 / 1.22
EV/EBITDAAt Loss
EV/Revenue1.10
10Y Low / Med / High0.00 / 19.67 / 221.07
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$0.84
Net Current Assets / Share
$0.56
Graham Net-Net
$0.05
Cash / Share
$0.39
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -540.00 | -379.46 | -262.43 | -64.42 | -0.35 | -0.17 | -0.10 | |
| P/S Ratio | 12.46 | 23.43 | 121.82 | 23.37 | 4.83 | 1.35 | 1.88 | |
| P/B Ratio | -1.55 | -1.55 | -1.15 | 1.22 | 0.73 | 0.39 | 0.60 | |
| EV/EBITDA | -125.80 | -45.21 | -23.40 | -2.77 | -0.18 | -0.00 | -0.15 | |
| EV/Revenue | 19.67 | 39.54 | 221.07 | 15.60 | 2.35 | 0.00 | 1.10 |
Analyst Estimates & Quality
Altman Z-Score
-21.76
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $1.0M | $1.4M | $2.0M |
| Net Income | -$2.1M | -$2.4M | -$402.1K |
| EPS | $-3.16 | $-3.58 | $-0.60 |
| # Analysts (EPS) | 1 | 1 | 1 |